Literature DB >> 20117094

Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.

Sehyoun Yoon1, Jai Sung Noh, Se-Young Choi, Ja-Hyun Baik.   

Abstract

Many atypical antipsychotic drugs cause weight gain, but the mechanism of this weight gain is unclear. To dissect the role of the dopamine D2 receptor (D2R), an important receptor in the pharmacology of antipsychotic drugs, we analyzed the effect of olanzapine, risperidone, and ziprasidone on changes in body weight and food intake in male wild-type (WT) and D2R knockout (D2R(-/-)) mice. The oral delivery of atypical antipsychotics, olanzapine (5 and 10mg/kg), risperidone (0.1 and 1.0mg/kg) and ziprasidone (10 and 20mg/kg) in both strains mice for 2 weeks suppressed body weight gain, except for olanzapine treatment in D2R(-/-) mice. Olanzapine treatment suppressed body weight gain and decreased food intake in WT mice, but also reduced fat body mass and locomotor activity, whereas D2R(-/-) mice did not show these changes. Ziprasidone and risperidone treatment produced similar responses in WT and D2R(-/-) mice. These data suggest the involvement of D2R in the effect of olanzapine on metabolic regulation. Further studies are required to explore the implications of D2R activity in antipsychotic-mediated metabolic complications. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117094     DOI: 10.1016/j.bbrc.2010.01.108

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.

Authors:  Ei Sejima; Atsushi Yamauchi; Tsuyoshi Nishioku; Mitsuhisa Koga; Kengo Nakagama; Shinya Dohgu; Kojiro Futagami; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

2.  Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice.

Authors:  Po-Hsun Hou; Geng-Ruei Chang; Chin-Pin Chen; Yen-Ling Lin; I-Shuan Chao; Ting-Ting Shen; Frank Chiahung Mao
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

3.  Impact of Chronic Risperidone Use on Behavior and Survival of 3xTg-AD Mice Model of Alzheimer's Disease and Mice With Normal Aging.

Authors:  Virginia Torres-Lista; Secundí López-Pousa; Lydia Giménez-Llort
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

4.  Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice.

Authors:  Hsiao-Pei Tsai; Po-Hsun Hou; Frank-Chiahung Mao; Chia-Chia Chang; Wei-Cheng Yang; Ching-Feng Wu; Huei-Jyuan Liao; Tzu-Chun Lin; Lan-Szu Chou; Li-Wei Hsiao; Geng-Ruei Chang
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

5.  Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine.

Authors:  Piao-Piao Huang; Wen-Qiang Zhu; Jing-Mei Xiao; Yi-Qi Zhang; Rong Li; Yang Yang; Li Shen; Fei Luo; Wen Dai; Ping-An Lian; Ya-Xin Tang; Juan-Li Ran; Xian-Sheng Huang
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.